3-C-(2-hydroxyethyl)-1,2:5,6-di-O-isopropylidene-D-allofuranose | 921202-53-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-C-(2-hydroxyethyl)-1,2:5,6-di-O-isopropylidene-D-allofuranose
• 英文别名: 1,2:5,6-di-O-isopropylidene-3-C-(1'-hydroxyethyl)-α-D-allo-1,4-furanose；(3aR,5R,6R,6aR)-5-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-6-(2-hydroxyethyl)-2,2-dimethyl-5,6a-dihydro-3aH-furo[2,3-d][1,3]dioxol-6-ol
• CAS: 921202-53-1
• 化学式: C₁₄H₂₄O₇
• 分子量: 304.34
• InChiKey: VGRYISKTJJNXIG-YNXVLUOKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  86.6
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  3-C-(2-hydroxyethyl)-1,2:5,6-di-O-isopropylidene-D-allofuranose 在 palladium dihydroxide 、 Grubbs catalyst first generation 吡啶 、 四氧化锇 、 sodium azide 、 水 、 氢气 、 sodium hydride 、 溶剂黄146 、 N-甲基吗啉氧化物 、 三乙胺 、 sodium iodide 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 丙酮 、 叔丁醇 为溶剂， -20.0~100.0 ℃ 、101.33 kPa 条件下， 反应 136.83h， 生成 [(1R,2R,6R,8R,9S,10S)-1-(2-azidoethyl)-10-hydroxy-4,4-dimethyl-3,5,7,12-tetraoxatricyclo[6.4.0.02,6]dodecan-9-yl] 4-methylbenzenesulfonate
  参考文献：
  名称：

  Structure-Based Organic Synthesis of a Tricyclic N-Malayamycin Analogue

  摘要：

  The solid-state structure of crystalline malayamycin A reveals a urea substituent that bisects the plane of the chairlike tetrahydropyran subunit. On the basis of this topological feature, we synthesized a tricyclic N-nucleoside analogue in which an ethano bridge linked the urea NH group with the ring junction of the bicyclic tetrahydrofuropyran unit.

  DOI：

  10.1021/jo061904r
• 作为产物：
  描述：

  1,2:5,6-二-o-异亚丙基-alpha-d-ribo-3-己呋喃核糖 在 臭氧 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 为溶剂， 反应 12.5h， 生成 3-C-(2-hydroxyethyl)-1,2:5,6-di-O-isopropylidene-D-allofuranose
  参考文献：
  名称：

  Structure-Based Organic Synthesis of a Tricyclic N-Malayamycin Analogue

  摘要：

  The solid-state structure of crystalline malayamycin A reveals a urea substituent that bisects the plane of the chairlike tetrahydropyran subunit. On the basis of this topological feature, we synthesized a tricyclic N-nucleoside analogue in which an ethano bridge linked the urea NH group with the ring junction of the bicyclic tetrahydrofuropyran unit.

  DOI：

  10.1021/jo061904r

文献信息

• MONOSACCHARIDE DERIVATIVES
  申请人：Sattigeri Jitendra Viswajanani

  公开号：US20080114031A1

  公开（公告）日：2008-05-15

  The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, Ulcerative colitis, acne, atherosclerosis, cancer, pruritis and allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, Ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.

  本发明涉及单糖衍生物作为抗炎剂。本发明的化合物可用于抑制和预防炎症及相关病理，包括炎症和自身免疫疾病，如支气管哮喘、类风湿性关节炎、I型糖尿病、多发性硬化症、异体移植排斥、银屑病、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒和过敏性鼻炎。还提供了包含本发明披露的化合物的药物组合物，以及使用这些化合物治疗支气管哮喘、慢性阻塞性肺病、类风湿性关节炎、多发性硬化症、I型糖尿病、银屑病、异体移植排斥、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒、过敏性鼻炎以及其他炎症性和/或自身免疫障碍的方法。
• Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents
  申请人：Sattigeri Vishwajanani Jitendra

  公开号：US20090048186A1

  公开（公告）日：2009-02-19

  The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis and allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.

  本发明涉及单糖衍生物作为抗炎剂。本发明的化合物可用于抑制和预防炎症及相关病理，包括炎症和自身免疫疾病，如支气管哮喘、类风湿性关节炎、I型糖尿病、多发性硬化症、异体移植排斥、银屑病、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒和过敏性鼻炎。还提供了含有本发明披露的化合物的药物组合物，以及使用这些化合物治疗支气管哮喘、慢性阻塞性肺病、类风湿性关节炎、多发性硬化症、I型糖尿病、银屑病、异体移植排斥、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒、过敏性鼻炎以及其他炎症性和/或自身免疫障碍的方法。
• MONOSACCHARIDE DERIVATIVES AS ANTI-INFLAMMATORY AND/OR ANTI-CANCER AGENTS
  申请人：Ranbaxy Laboratories Limited

  公开号：EP1842855A2

  公开（公告）日：2007-10-10

  The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, Ulcerative colitis, acne, atherosclerosis, cancer, pruritis and allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type 1 diabetes, psoriasis, allograft rejection, inflammatory bowel disease, Ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.

  本发明涉及作为抗炎剂的单糖衍生物。本发明的化合物可用于抑制和预防炎症及相关病症，包括炎症和自身免疫性疾病，如支气管哮喘、类风湿性关节炎、I 型糖尿病、多发性硬化症、异体移植排斥反应、牛皮癣、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒症和过敏性鼻炎。还提供了含有本文公开的化合物的药理组合物，以及使用该化合物治疗支气管哮喘、慢性阻塞性肺病、类风湿性关节炎、多发性硬化症、1型糖尿病、银屑病、异体移植排斥反应、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒症、过敏性鼻炎和其他炎症性和/或自身免疫性疾病的方法。
• Synthesis of anomeric 1,5-anhydrosugars as conformationally locked selective α-mannosidase inhibitors
  作者：Rajendra S. Mane、Sougata Ghosh、Shailza Singh、Balu A. Chopade、Dilip D. Dhavale

  DOI：10.1016/j.bmc.2011.09.046

  日期：2011.11

  Anomeric 1,5-anhydrosugar 2 was synthesized from D-glucose derived N-Cbz protected aminodiol 8. The key step involves, acid catalyzed hydrolysis of 1,2-acetonide group in 8 to get hemiacetal that concomitantly undergoes formation of the pyranose ring by attack of C-3 hydroxyethyl group on anomeric C-1, leading to the formation of dioxabicyclo[3.2.1]octane skeleton which on hydrogenolyis gave 2. The glycosidase inhibitory activities of hydroxy-and amino-substituted anomeric 1,5-anhydrosugars 1 and 2, respectively, showed selective inhibition of alpha-mannosidase. These results were substantiated by molecular docking studies using WHAT IF software and AUTODOCK 4.0 program. (C) 2011 Elsevier Ltd. All rights reserved.